Hc Advisors, LLC Ascendis Pharma A/S Transaction History

Hc Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$123.45 - $159.4 $182,582 - $235,752	1,479 New	1,479 $223,000
Q4 2022 Feb 08, 2023	SELL	$99.42 - $131.97 $49,710 - $65,985	-500 Reduced 19.42%	2,075 $253,000
Q3 2022 Nov 10, 2022	SELL	$84.03 - $110.23 $5,966 - $7,826	-71 Reduced 2.68%	2,575 $266,000
Q2 2022 Aug 08, 2022	BUY	$78.08 - $117.61 $156 - $235	2 Added 0.08%	2,646 $246,000
Q1 2022 May 06, 2022	SELL	$102.18 - $135.75 $29,836 - $39,639	-292 Reduced 9.95%	2,644 $310,000
Q4 2021 Feb 02, 2022	BUY	$127.1 - $169.66 $71,811 - $95,857	565 Added 23.83%	2,936 $395,000
Q3 2021 Oct 29, 2021	SELL	$112.67 - $176.92 $9,464 - $14,861	-84 Reduced 3.42%	2,371 $378,000
Q2 2021 Aug 09, 2021	SELL	$121.62 - $145.29 $11,189 - $13,366	-92 Reduced 3.61%	2,455 $323,000
Q1 2021 May 07, 2021	BUY	$124.92 - $173.33 $6,246 - $8,666	50 Added 2.0%	2,547 $328,000
Q4 2020 Feb 08, 2021	BUY	$151.2 - $182.76 $29,030 - $35,089	192 Added 8.33%	2,497 $416,000
Q3 2020 Nov 04, 2020	BUY	$134.29 - $154.32 $34,646 - $39,814	258 Added 12.6%	2,305 $356,000
Q2 2020 Aug 12, 2020	BUY	$110.87 - $156.01 $226,950 - $319,352	2,047 New	2,047 $303,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Hc Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Hc Advisors, LLC with notifications on news.